← All trials
NCT06013345
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2023
- Primary completion
- Oct 1, 2024
- Completion date
- Feb 1, 2025
- First posted
- Aug 28, 2023
- Last posted
- Nov 28, 2023
- Enrollment
- 126
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Charles UniversityLead sponsor
- Charles UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.